🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. ECULIZUMAB , ECULIZUMAB

    Pari Pharma GmbH

    Adult patients with aHUS associated with HE and severe kidney involvement (needing dialysis or serum creatinine ≥ 354μM)

    phase 3 small molecule active

    1 trial

  2. ELECTROLYTES , VIALEBEX 200 g/L, solution pour perfusion

    Pari Pharma GmbH

    Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

    phase 3 small molecule active

    1 trial

  3. ELX/TEZ/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    19 trials

  4. ENOXAPARIN

    Pari Pharma GmbH

    Allograft vascular thrombosis

    phase 3 small molecule active

    1 trial

  5. ENTECAVIR , VAY736, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled pen, TENOFOVIR ALAFENAMIDE , -, VAY736, TENOFOVIR DISOPROXIL

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  6. EPREX®

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Renal Anemia

    phase 3 small molecule completed

    1 trial

  7. ESTREVA 0,1 %, gel, ANDROGEL 16,2 mg/g, gel, PROVAMES 1 mg, comprimé pelliculé

    Pari Pharma GmbH

    gender dysphoria

    phase 3 small molecule active

    1 trial

  8. ETOPOSIDE

    Pari Pharma GmbH

    Hemophagocytic lymphohistiocytosis (HLH)

    phase 3 small molecule active

    1 trial

  9. ETOPOSIDE , DEXAMETHASONE

    Pari Pharma GmbH

    Hemophagocytic lymphohistiocytosis (HLH)

    phase 3 small molecule active

    1 trial

  10. EVEROLIMUS

    Novartis Pharmaceuticals

    Refractory seizures associated with tuberous sclerosis complex

    phase 3 small molecule active

    1 trial

  11. Early activity and mobilisation

    Zealand Pharma A/S

    Critically Ill, Mechanically Ventilated

    phase 3 other completed

    1 trial

  12. Eliquis 5 mg film-coated tablets, ACETYLSALICYLIC ACID

    Pari Pharma GmbH

    Aortic bioprothesis implanted patient for valvular heart disease

    phase 3 small molecule active

    1 trial

  13. Empagliflozin 10 MG

    COLLEGIUM PHARMACEUTICAL, INC

    Acute Decompensated Heart Failure

    phase 3 small molecule active

    1 trial

  14. Empagliflozin 20 mg

    COLLEGIUM PHARMACEUTICAL, INC

    Metabolic Syndrome

    phase 3 small molecule active

    1 trial

  15. Endoxifen, Identical placebo tablets of Endoxifen manufactured by Intas Pharmaceuticals Limited, India. The placebo tablets were manufactured using the same excipients and the manufacturing process of endoxifen tablets. Like endoxifen 8 mg tablets, the placebo tablets are green coloured, round shape, biconvex, enteric coated tablets plain on both sides. The placebo for Endoxifen Tablets 8 mg was manufactured following the same procedure as the drug product without using endoxifen citrate.

    Lacuna Pharma Pty Ltd

    Bipolar I Disorder

    phase 3 small molecule active

    1 trial

  16. Enema transplant of fecal microbiota, Placebo Enema transplant of fecal microbiota

    Pari Pharma GmbH

    Adult patients with ulcerative colitis diagnosed for at least 3 months

    phase 3 small molecule active

    1 trial

  17. Enzastaurin

    AYTU BIOPHARMA, INC

    Vascular Ehlers-Danlos Syndrome

    phase 3 small molecule on hold

    1 trial

  18. Epidyolex 100 mg/ml oral solution

    Lacuna Pharma Pty Ltd

    Dravet Syndrome, Tuberous sclerosis complex, Lennox-Gastaut Syndrome

    phase 3 small molecule active

    1 trial

  19. Epinephrine HFA-MDI (E004)

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule completed

    1 trial

  20. Eplontersen

    IONIS PHARMACEUTICALS INC

    Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

    phase 3 small molecule active

    2 trials

  21. Eplontersen

    IONIS PHARMACEUTICALS INC

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule active

    1 trial

  22. Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).

    Lacuna Pharma Pty Ltd

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  23. Estradiol

    Teva Pharma GmbH

    Dyspareunia

    phase 3 small molecule completed

    1 trial

  24. Estradiol Vaginal Tablets 10 mcg

    Amneal Pharma Europe Ltd

    Atrophic Vaginitis Due to Menopause

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources